

Recommendations from York and Scarborough Medicines Commissioning Committee 15 October 2014 – Vale of York CCG

The recommendations below represent revisions to the formulary following a review of the joint York and Scarborough net formulary with the epilepsy specialists (adult/children) for York & Scarborough Teaching Hospital to ensure all appropriate formulary items are listed. This list is intended to provide an update on the classification of medicines e.g. amber = shared care stating the specialist's responsibility.

Drug name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact
Clonazepam	Epilepsy	Remove from formulary – not commissioned	Formulary review - epilepsy specialists for adult/children services advise this is not used	Black	Nil new
Eslicarbazepine	Epilepsy	Non formulary	Formulary review - epilepsy specialists for adult/children services advise this is not used	Black	Nil new
Perampanel	Epilepsy	Revised commissioning position	Formulary review - Specialist initiation and supply for initial three months with treatment as per treatment care plan	Amber (formerly red)	Current 12 month spend £4,656
Primidone	Epilepsy	Formulary addition	Formulary review – for continuation of existing patients only	Amber	Current 12 month spend £17,779
Rufinamide	Epilepsy	Formulary addition	Specialist initiation and supply with treatment as per the care plan.	Amber	Current 12 month £3,148
Valproic acid	Epilepsy	Non formulary	Epilepsy specialists for adult/children services advice.	Black	Nil new for this speciality

Some antiepileptic drugs should be prescribed by brand – further details can be found via this link to the [MHRA](#). Further work is ongoing with secondary care on this.